Navigating Treatment Options for Patients With Relapsed/Refractory CLL
Danielle M. Brander, MD, assistant professor of medicine at Duke University School of Medicine and member of the Duke Cancer Institute, discusses a major challenge in the field of chronic lymphocytic leukemia. She says the biggest challenge to overcome in the treatment of patients with CLL is navigating areas where research is not yet mature.
Danielle M. Brander, MD, assistant professor of medicine at Duke University School of Medicine and member of the Duke Cancer Institute, discusses a major challenge in the field of chronic lymphocytic leukemia (CLL). She says the biggest challenge to overcome in the treatment of patients with CLL is navigating areas where research is not yet mature.
For example, it is still unclear how some novel agents in the frontline setting do long-term for favorable-risk patients. Additionally, agents for the relapsed/refractory setting have been randomized to chemotherapy in phase II trials, but how can these agents be compared to decide the best treatment?
